Literature DB >> 34779025

Effect of exercise on serum neutrophil gelatinase-associated lipocalin concentration in racehorses.

Marnie Flick1, Anne M L Vinther2, Stine Jacobsen3, Lise C Berg3, Marina Gimeno1, Denis Verwilghen1, Wade Howden1, Kate Averay1, Gaby van Galen1.   

Abstract

Serum neutrophil gelatinase-associated lipocalin (sNGAL) is a marker of renal injury, and its concentrations are affected by inflammation. Therefore, it could serve as a useful biomarker of disease or fitness in high-level competition. However, it has not yet been determined if sNGAL concentrations are affected by exercise. The aim of this study was to determine whether concentrations of equine sNGAL were affected by 1000 m galloping as the form of exercise used in the study. Pre- and post-gallop sNGAL, serum amyloid A, and creatinine concentrations were evaluated in 14 healthy Thoroughbred racehorses. The results showed that short, high-intensity exercise did not significantly affect sNGAL concentrations in healthy horses (P = .42), and no significant difference was found in either creatinine or serum amyloid A before and after galloping (P > .05). Therefore, it was determined that sNGAL was not influenced by the type of exercise used in the study and could have the potential to be used as a routine laboratory screening tool in horses even after strenuous exercise. Future research should clarify its use in a larger population and a broader range of equine sport disciplines, including endurance-related exercise.
© 2021 American Society for Veterinary Clinical Pathology.

Entities:  

Keywords:  equine; inflammation; kidney; screening

Mesh:

Substances:

Year:  2021        PMID: 34779025     DOI: 10.1111/vcp.13027

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  1 in total

Review 1.  Biomarkers of Kidney Disease in Horses: A Review of the Current Literature.

Authors:  Gaby van Galen; Emil Olsen; Natalia Siwinska
Journal:  Animals (Basel)       Date:  2022-10-05       Impact factor: 3.231

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.